Podcasts about dalriada

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Diana Kraskouskaya, co-founder and CEO of Dalriada Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Diana, covering: Exactly what ‘the Toronto paradox' is... How two, seed-funded failures, led to identifying a gap in the market along with access to a rich talent pool The challenges and realities of starting, growing and scaling a CRO business to over 100 people Advice for other females looking to forge an entrepreneurial career in the drug development space Diana brings years of leadership and hands-on cross-disciplinary biotech and drug discovery experience spanning areas of company building, scientific & IP program strategy, and operations. She completed an Honors BSc Degree in Molecular Biology and PhD in Medicinal Chemistry from the University of Toronto and is a co-founder of two other biotechs, which have raised > $10 M in VC funding. Diana is the recipient of several entrepreneurship awards, including the RBC Prize for Innovation & Entrepreneurship and the 2018 MNP Future Leaders Awards. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

Julian Hobday, Origination & Execution Director, LGRI, Adolfo Aponte, Managing Director, Lincoln Pensions and Tom Lukic, Trustee, Dalriada, discuss what happens when a pension scheme's corporate sponsor is acquired by another company and the Mergers & Acquisitions (M&A) agreement includes provisions regarding the pension scheme that makes the  sale conditional on the removal of future DB risk. The episode focuses on a recent transaction completed by Legal & General in November 2020, where Lincoln provided strategic advice to the seller.

In ‘Whiskey Talkin' broadcaster Mark Thompson teams up with historian Dr Fionnan O'Connor to discover the fascinating, and almost forgotten story of what was once the greatest whiskey industry in the world. Irish whiskey is now enjoying a 21st century renaissance, with the fastest growing spirit sales in the world. Once a global player, whose industrial success was almost forgotten, it is a drink with a chequered past. Rogues and rebels, migration and moonshine, taxes and temperance – they're all part of a fascinating story that's shared between Ireland, Scotland and America. Ulster and Northern Ireland are at the heart of this story – from the Kingdom of Dalriada and the poitin masters of Donegal, to Northern Ireland's 21st century pioneers, currently resurrecting the brands and blends once counted among the most famous whiskeys in the world. Though Belfast's industrial golden age is more often associated with ship building and linen production, they reveal just how significant a role whiskey had in the growth of Belfast, where the industry once employed thousands – and generated millions. The film uncovers forgotten links between Ulster's whiskey makers, and our neighbour across the narrow sea, revealing just how much Scotland's whisky story owes to the north of Ireland, and looking back to a time when Irish whiskey exports outsold Scotch by three to one. Graphic designer Mark's fascination with branding and advertising opens a door on our industrial past, as he discovers just how much the story of whiskey connects with the history and heritage of the Ulster-Scots. From a tiny craft distiller in the Mournes to the historic home of old Bushmills, Mark and Fionnan explore a broken history, meeting with the enthusiasts who are rediscovering forgotten recipes and re-creating some of the great spirits from Irish whiskey's golden age. Whiskey Talkin' is on BBC https://www.bbc.co.uk/iplayer/episode/m000wqgc/whiskey-talkin, and is a Northern Star Pictures Production, made with assistance from the Northern Ireland Screen Ulster-Scots Broadcast Fund. --- Send in a voice message: https://anchor.fm/irishwhiskeyreview/message

Podcast: Illiquid asset classes might seem attractive in theory, but there would be difficulties establishing them in a defined contribution pension portfolio, even if all the regulatory burdens were removed. Brian Henderson, partner and director of consulting at Mercer, is joined by Shola Salako, professional trustee at Dalriada, to discuss alternatives, putting the S in ESG, and fixing the problems with chair’s statements. See acast.com/privacy for privacy and opt-out information.

Exkluzív interjúnkban ismét olyan dolgok hangoztak el a zenekar életéből, amiről még nem beszélt a Dalriada. Eddig. Köszönjük a bizalmat és azt a rengeteg élményt, amit sikerült feleleveníteni műsorunk alkalmával. Innen folytatjuk velük a jövőben, kitartást kívánunk a hazánkban meghonosított folk metált játszó Dalriadanak a jelenlegi helyzet túléléséhez.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! ¿Dónde terminará la satisfacción intelectual y comenzará la gratificación espiritual? ¿Cuál es el origen del cetro? El tirso del dios Dionisio. Los símbolos Templarios. Los antiguos egipcios. Herramientas de poder degeneradas en vacíos entretenimientos sociales. La sinarquía. Los reyes magos y el don de sanación. El séptimo hijo varón. Las monarquías de sangre azul. La función de la corona. La gemoterapia. El Trono de la Coronación. La Piedra del Destino (o Piedra de Scone). Egrégoros. Razones políticas, económicas y *también* esotéricas. La gaita en Galicia y las Islas Británicas. Los Milesianos y los Tuatha Dé Danann. ¿Cúchulainn es Kukulkán? El Reino de Dalriada. El reino de los Anglos. Los ingleses. Tuvo efectos mágicos la rotura de la Piedra del Destino? Más información en: https://alfilodelarealidad.com/Escucha este episodio completo y accede a todo el contenido exclusivo de Al Filo de la Realidad. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/3844

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! ¿Dónde terminará la satisfacción intelectual y comenzará la gratificación espiritual? ¿Cuál es el origen del cetro? El tirso del dios Dionisio. Los símbolos Templarios. Los antiguos egipcios. Herramientas de poder degeneradas en vacíos entretenimientos sociales. La sinarquía. Los reyes magos y el don de sanación. El séptimo hijo varón. Las monarquías de sangre azul. La función de la corona. La gemoterapia. El Trono de la Coronación. La Piedra del Destino (o Piedra de Scone). Egrégoros. Razones políticas, económicas y *también* esotéricas. La gaita en Galicia y las Islas Británicas. Los Milesianos y los Tuatha Dé Danann. ¿Cúchulainn es Kukulkán? El Reino de Dalriada. El reino de los Anglos. Los ingleses. Tuvo efectos mágicos la rotura de la Piedra del Destino? Relacionado: Más información sobre "egrégoros": https://alfilodelarealidad.wordpress.com/?s=egr%C3%A9goro

The Dalriada has been a fundamental part of life in Portobello for many years. Music has played a large part of that with both organised and impromptu sessions regularly taking place in the bar. The Sunday Sessions were particularly popular with musicians and the public alike. They were the brainchild of Jed Milroy who was looking for a new venue – he had been hosting sessions at a pub near the university. The Dalriada not only welcomed him – but also played cupid because Jed met Jo and they became a duo in every sense of the word. The Dalriada as we knew it may never return when life returns to the new normal. But the Sunday Sessions have continued online since the lock down. So today, we’re telling the story of Jed and Jo, the story too of those Sunday Sessions and their importance to the community into the future.Jed and Jo are also running their own regular online sessions at 9 o’clock on a Friday using Facebook Live. The music in this episode comes from one of those. The couple are also entertaining the other residents in their tenement by singing from their front door and are also raising money for the charity North Edinburgh Arts.Jed and Jo’s Facebook page can be found here: https://tinyurl.com/wto4m96It’s where you can find information about their next live sessions.And the Sunday Sessions online can be found here: https://tinyurl.com/wzssjdkTheir charity’s link is here: https://northedinburgharts.co.uk/

Hosted by Raymond McCullough, in Downpatrick, Co. Down, Northern Ireland  with music from:   Jason Macdonald  (Cape Breton Island, NS, Canada) – ‘Storm on the Way’ (Got a Ways to Go)   Didgericruise (Arizona, USA) – ‘Over the Ganges Waterfall' (Didgericruise)   The Rolling Kings (Newfoundland & Labrador, Canada) – ‘Raise a Glass’ (Raise a Glass)   Dark Patrick (Ukraine) – ‘Lachin Y Gair’ (Fainne Gael An Lae)   Rapidly Agin’ (Northern Ireland, UK) – ‘Duelling Banjos’ (A Few Dollars More)   Jay Wars & the Howard Youth (Melbourne, Australia) – 'Abraham Brown’ (Love in the Time of Fear)   Julie Henigan (Missouri, USA) – ’Hoban’s Hill’ (American Stranger)   Billy Brandt & Sarana VerLin (Michigan, USA) – ’Knock On Wood’ (Live From Billy's Basement)   Catherine Duc (Melbourne, Australia) – ‘Seallaibh Curraigh Eoghainn (Owen’s Boat)’ (Voyager)   Produced by Precious Oil Productions Ltd for Celtic Roots Radio

Nemrég kiszúrtam, hogy Szög Esztergomban pihen. Írtam neki, hogy akkor már igazán leülhetnénk dumálgatni egyet! Sajnos nem jött össze, viszont nem vetettük el a dolgot, méghozzá olyannyira nem, hogy most beiktattuk, és a közelgő jubileumi koncert kapcsán kicsit kiveséztük a Dalriada múltját, jelenét és persze a jövőjét is. Vendég: - Szabó Gergely "Szög" (Dalriada, és még sok más) Ha bármi észrevétel, hozzáfűznivaló, témaötlet van, azt a rics@ricsandgreen.hu címre küldhetitek! :) Ha szeretnéd, hogy több Ric$Cast készüljön, akkor támogasd az adást a patreon.com/ricscast oldalon! Köszönöm! :) Felvétel: Pataki László, Genezáret Stúdió Master: Gémes Norbert Intro zene: Fellegi Ádám Intro hangok: Lukács Laci, Sidi, Fejes Tomi, Big Daddy L, Paddy Ric$: www.facebook.com/szenegetorichard/ ricsandgreen.hu Szög: www.facebook.com/gergelyszabomusic/ Dalriada: www.facebook.com/Dalriadahu/ dalriada.hu/

Bonus Language Stories?! Yup. Woohoo! This episode, I chat with Àdhamh Ó Broin who is working to bring Dalriada Gaelic, an endangered dialect of Scottish Gaelic, back from the brink. The Video Click here to watch the sister video to this podcast episode. (https://www.youtube.com/watch?v=5n_0DIgt2jM) To keep track of future episodes in video form, click here to subscribe on YouTube. Support The Show The best thing you can do right now to support the project is threefold, and if you've ever listened to any podcast before, I'm sure you'll be familiar with what I'm about to say! Subscribe - by subscribing to the Language Stories podcast in your favourite place and YouTube for the sister videos, you're going to keep up with all future episodes. Woop! Review - when it comes to the tech stuff, reviews are pretty important. Reviews help to tell iTunes that people like the podcast, and that helps to raise the profile so that new people can find it easily. Yay! Tell a friend - word of mouth still wins! If you know someone who would love Language Stories, tell them about it. And if they're new to podcasts, walk them through the process to subscribe them. Woohoo! To make it as easy as possible to share the podcast, click here to tweet about episode. Share Your Story If you have a Language Story you'd love to share, or if you know someone that does, get in touch. I always love to hear from you! Your feedback helps to shape future episodes so thank you. Special Guest: Àdhamh Ó Broin - Dalriada Scottish Gaelic Consultant.

Bonus Language Stories?! Yup. Woohoo! This episode, I chat with Àdhamh Ó Broin who is working to bring Dalriada Gaelic, an endangered dialect of Scottish Gaelic, back from the brink. The Video Click here to watch the sister video to this podcast episode. (https://www.youtube.com/watch?v=5n_0DIgt2jM) To keep track of future episodes in video form, click here to subscribe on YouTube. Support The Show The best thing you can do right now to support the project is threefold, and if you've ever listened to any podcast before, I'm sure you'll be familiar with what I'm about to say! Subscribe - by subscribing to the Language Stories podcast in your favourite place and YouTube for the sister videos, you're going to keep up with all future episodes. Woop! Review - when it comes to the tech stuff, reviews are pretty important. Reviews help to tell iTunes that people like the podcast, and that helps to raise the profile so that new people can find it easily. Yay! Tell a friend - word of mouth still wins! If you know someone who would love Language Stories, tell them about it. And if they're new to podcasts, walk them through the process to subscribe them. Woohoo! To make it as easy as possible to share the podcast, click here to tweet about episode. Share Your Story If you have a Language Story you’d love to share, or if you know someone that does, get in touch. I always love to hear from you! Your feedback helps to shape future episodes so thank you. Special Guest: Àdhamh Ó Broin - Dalriada Scottish Gaelic Consultant.

080 | Pursuing cures and advancing innovation   Welcome to another episode of Biotechnology Focus radio! I am your host – Michelle Currie – here to give you the rundown on what’s been happening on Canada’s biotech scene. It has been a busy last couple of weeks as the new genomics cloud platform was launched, a researcher from Roche Canada shares her input on future of innovation in cancer care, and the fight against cancer innovation trust invests almost half a mil in Ontario research technologies.   +++++  The world is opening up to the idea of genome sequencing. What was once a far-fetched idea is now beginning to materialize – and we are only at the tip of the iceberg. Information technology like Facebook, Google, Wikipedia and Uber are all prime examples of impactful software platforms that connect people with data that have set the stage for the next act.  When you look at where DNA sequencing began back in the 1970’s with the “Sanger sequencing method” as a process of determining the order of bases in the length of DNA, we’ve come a long way. But still, researchers are at the forefront of this revolution of gathering our personalized genetic information and using it to power the next generation of safer and more effective “precision” medicines.  This is where Marc Fiume and his team from DNAstack, a Toronto-based cloud genomics company, have their role to play. Started in 2014, the company began work with some exciting researchers from around Canada whose hot topics included autism and cancer research. But constantly they were told that the researchers just didn’t have enough samples to make sense of all the data they were collecting and that they really needed a platform that would connect them with other researchers globally who found themselves in the same position. Inspired by the concept of Facebook, they decided to build their own platform where genetic research could transpire among researchers worldwide.  He refers to the lack of data access as “potentially keeping life-saving information in a basement server room” and is one of his biggest frustrations when it comes to genomic research. Unveiling the sequence of a genome is challenging, time-consuming and expensive. Perhaps that is the reason why such a platform can no longer be just a notion, but become a mandatory tool so we can further our knowledge unified, instead of trying to connect the dots apart.  Genome sequencing is a lot like “decoding” of a foreign script or ciphering out a code of each individual’s personal genome. It is a long string of letters that forms a sort of molecular blueprint that is unique for each of us. These “strings” of letters are about six billion long, and currently, researchers are only grasping about a very small per cent of what those letters represent. This is why the need for sharing information should be a necessity.  In an attempt to break this societal self-inflicted mold, Marc worked with Dr. Stephen Scherer from The Centre of Applied Genomics on the “Personal Genome Project Canada” to facilitate the publication of health and genome records online for free. The intention being that whether you are sick or healthy, it is incredibly useful personally and for the research community to have your genome sequenced. Perhaps you have a predisposition to a potentially harmful genetic disease that you were not aware of before and could catch it before it starts, or if you are a carrier, or if you simply want to learn more about your ancestry. All of this is possible with genome sequencing. While some may not be ready to have theirs published online, it could still be made available to you in the privacy of your own home.  Marc and Ryan Cook, the other co-founder of DNAstack, have both tried to decrease the unease attached to publicly airing one’s genome sequence by publishing their own. “It’s about empowering and making key decisions about their healthcare in a way that’s not scary and also to break down barriers about data sharing,” comments Marc.  There are now 56 genome researchers that are bearing it all for the world to see, and encouragingly are following up on some of the data that they have found.  DNAstack recently launched their Canadian Genomics Cloud platform that is designed to better connect data, researchers and systems across the country to accelerate genomic discoveries and the implementation of precision medicine. It was invented by Canadian leaders with decades of experience in genomics, sequencing, cloud computing, software, security, and policy to democratize access to best-in-class infrastructure while respecting the unique national and provincial requirements for data privacy and security. Their aim is to service the needs of Canadian genome scientists from research institutions, clinical laboratories, pharmaceutical companies, hospitals, and industry.  The hope is to demonstrate that Canada now does have the capacity to do a precision medicine initiative at scale. Canada is really ready for this.” – says Marc.   +++++  For most of us, the start of a new year is a natural time to reflect on our progress as individuals. We take stock of the lives we’ve lived, the advances we’ve made, the impact we’ve had on those around us and the steps we need to take in the year ahead to achieve our goals.   For the Pharmaceutical and Biotechnology industry, the start of the new year is much the same. Standing at the doorstep of 2018, many of us who have spent our lives trying to advance healthcare around the globe believe that we are at a point in our careers, where science is progressing at a rapid rate.  In fact, some of us would venture that science is progressing at a rate that is outpacing our ability – as healthcare providers, as governments, as payers and as hospital institutions – to integrate these cutting-edge advances into clinical practice. While this reality poses significant challenges, it’s exciting to be on the threshold of so many unprecedented discoveries and novel treatment approaches for some of the world’s most devastating diseases.  The field of biotechnology is rich with discoveries that will have a dramatic impact on Canadians in 2018 and beyond. However, there are three key developments in the area of oncology in which we can expect to see some of the most transformative and immediate changes. These include:  the expanded role of diagnostics to optimize treatment choice;  the adoption of histology-agnostic treatment approaches; and  the next phase of true precision medicine     Expanded Role of Diagnostics  In recent years, the use of diagnostic tests within the Canadian cancer care setting has become an increasingly important practice, particularly for guiding treatment decisions and optimizing the patient’s chances for positive outcomes. In fact, it’s estimated that nearly 70 per cent of all treatment decisions today involve a pathology and/or laboratory investigation.  While the role of predictive biomarker testing has already been well established for some time in certain tumour types (such as HER2 in breast cancer or EGFR and ALK in lung cancer) we are witnessing the emergence of two trends that could further enhance patients’ care and their experience with our healthcare system. These include the ability to simultaneously look beyond a single biomarker through genomic profiling, and the viability of liquid/blood-based biomarker testing.  In 2018 we can expect to see a continued shift among healthcare providers to rely more on comprehensive genomic profiling to map each patient’s unique genomic profile to identify alterations across hundreds of genes known to be relevant in the development and progression of cancer. This broad approach optimizes the use of the available tumour tissue and provides physicians with the most comprehensive information to help guide their treatment selection. There is particular value in this approach for patients who have exhausted all standard treatment options or for those with rare forms of cancer with limited known effective treatment options.  Canadian institutions, like the British Columbia Cancer Agency, University Health Network in Toronto and The Jewish General Hospital in Montreal among many others, have already begun to demonstrate international leadership in this area with their in-house testing platforms and world-class genomic research programs.  We are also seeing the emergence of third-party molecular information providers, such as Foundation Medicine Inc., an organization that has partnered with Roche to offer genomic tests to provide physicians with information about a tumour’s unique genomic profile based on an interrogation of over 300 genes. These external services provide options for institutions that may not have the internal capabilities to offer such testing services and for patients who are looking for more comprehensive diagnostic information. All of these efforts are striving to rapidly expand treatment options by matching patients with approved targeted therapies, immunotherapies, and clinical trials based on their tumour’s molecular profile.  The second emerging trend in the space of predictive biomarkers is blood-based testing, which offers physicians a less-invasive testing mechanism for cases, in which there is insufficient tissue available for analysis. This may also prove to be a better option when a traditional tissue biopsy is not feasible due to tumour location, when a patient is in poor health, or when a physician and/or patient simply prefer a non-surgical option. In addition to supporting initial treatment choice, blood-based testing may also offer physicians the potential for continued monitoring in the future, resulting in earlier detection of disease progression and an assessment of resistance mutations to inform subsequent lines of therapy.     A Change in Mindset  Further to the evolution of diagnostic technologies, the increasing prevalence of targeted medicines is fundamentally challenging the way cancer research is conducted.  We are no longer seeing only large randomized Phase III studies measuring overall survival for drug development, but more novel trial designs, including basket and umbrella studies, as well as smaller Phase II designs to measure the safety and efficacy of a drug.  These new study approaches are aimed to accelerate scientific advancement and are addressing the challenges that exist when the prevalence of a particular molecular alteration is so limited that traditional trials seeking a large bolus of patients simply aren’t feasible.  In a basket trial, the impact of a single treatment across a spectrum of tumour types harbouring a particular alteration can be investigated. In contrast, umbrella trials inverse the approach, where multiple treatments are studied in patients with a common tumour type but who are stratified by molecular subtype.  Close to home, the Canadian Profiling and Targeted Agent Utilization (CAPTUR) trial sponsored by the Canadian Clinical Trials Group in partnership with several pharmaceutical companies and academic institutions across the country is a combined basket/umbrella study enrolling patients of all cancer types who are stratified into different arms of the study to receive treatments based on the genomic profile of their tumours.  Studies like CAPTUR will fundamentally shift how physicians view cancer, forcing them to look less at the type of cancer (e.g., breast, lung, colorectal) and focus on the molecular structure of the tumour.  This histology-agnostic approach is one that is also gaining traction with regulatory authorities around the globe. In fact, the U.S. Food and Drug Administration (FDA) recently approved a PD-1 inhibitor to treat patients with any cancer type, provided their tumours were unresectable or metastatic and classified as microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR).  This approval represented a significant departure from the traditional evidence requirements expected from a regulatory body and opens the door for further discussions and opportunities in other countries.  The final development, which seems like a natural extension of our evolving mindset around the use of diagnostics and targeted medicines in oncology is our view regarding how medicines can be engineered to offer truly individualized treatments to patients.  Though personalized medicines and immunotherapies are no longer considered ‘new’ in the rapidly evolving clinical landscape, the emergence of two types of truly bespoke cancer therapies marry these concepts to create what many consider a bold step in our quest to cure cancer.  Recently, two chimeric antigen receptor (CAR) T-cell therapies were approved in the United States, ushering in the next wave of personalized cancer care. These therapies involve the genetic engineering and reinfusion of a patient’s own T-cells to fight their unique cancers.  While approved in specific hematologic cancers today, researchers are also exploring these therapies in many solid tumours and the hope remains that they will offer a whole new way to think of treatment in cancer.  Still in its infancy, the second area of significant research is personalized cancer vaccines developed and manufactured for an individual patient based on the molecular profile of their tumours. Where off-the-shelf cancer vaccines have failed in the past, there is hope that these custom, uniquely tailored vaccines, in combination with checkpoint inhibitor therapies will succeed in transforming cancer care.  Close  In closing, while it’s easy to become discouraged by the often necessary hurdles required to integrate transformative products into current clinical practice, there has never been a more exciting time for those of who have built a career in the biotechnology industry; and there has never been a more exciting time for those of who have waited for a cure to cancer – a disease that has ravaged many of our families and has taken many of our friends and loved ones.  The reality is that science will continue to outpace clinical practice. But the promise of these discoveries can be realized if we – as stakeholders within the healthcare system – are willing and open-minded to collaborate on solutions, especially as we look at the impact personalized medicines can have in therapeutic areas beyond oncology, offering meaningful solutions to an infinitely greater number of patients, enabling them to live longer, healthier lives.  +++++  The fight against cancer innovation trust announces four new recipients of funding through its prospects oncology investment competition. Those recipients are Dalriada Therapeutics Inc., 16-Bit Inc., a cancer biomarker study at the Ontario Institute for Cancer Research (OICR), and a virus-based therapeutic under development at the Ottawa Hospital and the University of Ottawa.  FACIT’s investments are imperative in bridging the capital gap often experienced by early-stage Ontario companies, helping corporations establish jobs and build roots in the province. The wide-ranging scope of the innovations, which span therapeutics, machine learning and biomarker development, reflect the rich talent pool within the Ontario oncology research community.  Dalriada is a Canadian start-up founded with a mission to develop small molecule-based therapeutic technologies to battle diseases for which current treatment strategies are suboptimal or non-existent. With broad expertise in drug discovery, their efforts are currently centred on the preclinical development of a novel class (DT1) of small molecule inhibitors in cancers of the blood and brain as well as the development of a natural product for topical treatment of psoriasis and other inflammatory skin disorders.  16-Bit, a start-up founded by two medical doctors from the University of Toronto’s Diagnostic Radiology Program, is developing a machine learning algorithm to automate triaging of screening mammograms for breast cancer detection. Their focus is to utilize modern developments in machine intelligence to improve the accuracy, reliability, and speed of medical image interpretation while decreasing cost and barriers to healthcare.  Diagnostics Development Program at OICR leader Dr. John Bartlett has developed a diagnostic gene test to predict which breast cancer patients can benefit from anthracycline chemotherapy and which patients can avoid the associated toxicity because the drug may not be effective against their cancer.  The Ottawa Hospital and the University of Ottawa have developed a tumour-destroying virus based on the Vaccinia virus which adds a micro-RNA payload to enhance cell killing against pancreatic cancer. This targeted therapy is expected to be more precise and less toxic than conventional therapies for this difficult-to-treat tumour.  The Prospects Oncology Fund delivers on FACIT and OICR’s shared vision of advancing breakthrough innovations to the benefit of patients and Ontario’s knowledge economy.  Translating early-stage innovations and positioning them to raise additional funding supports Ontario’s competitive position as a destination for biotechnology.  Congratulations to all the strong applicants and in particular these outstanding awardees in their quest to make a difference for patients living with cancer.  +++++  Well, that wraps up another episode of Biotechnology Focus radio. I hope you enjoyed it. If you have a story idea or would like to be on the show, please email me at press@promotivemedia.ca. To see the articles in full check out the website biotechnologyfocus.ca and laboratoryfocus.ca so you don’t miss a beat! Have a momentous week. From my desk to yours – this is Michelle Currie.      

If you've ever been to the Comedy Nights at the Dalriada, you'll have seen the host Steven Davidson in action. However, there's another side to his professional life as a performer that he's developing in the form of a podcast - "Looking back on a Life the Didn't Happen".

http://thecomedycast.com/ Lorcan McGrane's a comedian that I really admire, a man doing his own thing and on his own terms. Unlike many comedians that attach themselves to a scene in a certain city he's doing his own thing living in rural County Monaghan, a border county in the north of the Republic of Ireland, but it's not Northern Ireland, even though it is in Ulster and has a border with Northern Ireland, and all the counties of Northern Ireland are in Ulster. It's all a bit mad, Monaghan's a bit like that. Anyway, we kicked off the interview by talking about the McGrane surname, Id' read it was derived from a Scotsman who left the Kingdom of Dalriada on the Scottish isle of Jura. Lorcan put me in my place though and informed me that the name comes from McGrainne and explains why that's a bit unusual. We spoke about growing up and living in Co. Monaghan with that constant feeling that everyone is watching everything that everyone does, all the time. We spoke about not falling into the trap of so-called 'edgy comedy' and how comedy promoters seems to love phrases like 'no holds barred' and 'anything goes' but you're not allowed be racist or sexist, and you're not anyway coz only scumbags are racist and sexist. Lorcan revealed that remaining real and truthful to yourself brings out the best in comedy. Lorcan told me about the time he was asked to do a set in front of the local GAA crowd, which didn't really go down as well as had been hoped. We chatted too about two of Lorcan's favourite subjects, geek culture and films, in particular superhero movies. The commonalities of teaching and stand-up comedy get a mention too, Lorcan is a lecturer in pop culture and has done his fair share of substitute teaching too so we chat about that and what they have in common. The rise of 'fake news' gets a mention too, it's only coming to the fore now but Lorcan tells us it's been around for a good while. We speak about some of Lorcan's alter egos on stage, Dermot H. Dark Materials, Livid Lorcan and Defective Deckard 237 and how exploring themes through new characters can open up a whole new take on things. We spoke then about the advantages of being a stand-up comedians while living in Co. Monaghan, not too far from the Dublin and Belfast scenes but still too far away from them to fell connected to them and how ploughing his own furrow suits Lorcan down to the ground. Finally then we spoke about Lorcan's comedic influences and his advice for new comedians.

It's become one of the best music bars in Edinburgh. Every day, there are musicians - professional as well as local amateurs - performing, sometimes into the witching hour. There are jam sessions, new bands and family sing-a-long gatherings on a Sunday. But there's more to the Dalriada than just the music. It's used by all sorts of groups - from the monthly Dalriada Conversations, to wine tastings and gourmet evenings. There is something for everyone.

Take a journey through Scotland's history on this episode of Simply Scottish, featuring finalists from our Moment in Scottish History Contest. What happened to Rome's 9th Legion after they marched into the wild lands of Caledonia? Learn about the famed footprint at Dunadd, seat of the ancient kings of Dalriada. Discover the significance of Dun Nechtain and Athelstaneford, two key battles in early Scottish history. Relive important moments in the life of Robert the Bruce, and uncover important truths about the Massacre of Glencoe and the Act of Union with England. All this plus music from Sandy Meldrum, The Paul McKenna Band, The Corries, and more!

In this edition host David Gordon visits the French House Party in Carcassonne for a Gourmet Explorer cookery course, he also visit the Rhine Valley. Travelwriter John Sheridan attends the launch of the Dalriada Festival in Glenarm and Geoff Harrison reports from Helsinki. You can find the show page at facebook.com/travelbitesradio and on Twitter at @trvlbitesradio